|
|||||
|
|
Quantitative mass spectrometry for colorectal cancer proteomics |
|
| Authors: | Juan Martínez-Aguilar Jenny Chik Judith Nicholson Crystal Semaan Matthew J McKay Mark P Molloy |
| Affiliation: | 1. Australian Proteome Analysis Facility (APAF), Department of Chemistry & Biomolecular Sciences, Macquarie University, Sydney, Australia;2. Australian Proteome Analysis Facility (APAF), Department of Chemistry & Biomolecular Sciences, Macquarie University, Sydney, Australia
Correspondence: Dr. Mark P. Molloy, APAF, Macquarie University, Sydney 2109, Australia. E-mail: mmolloy@proteome.org.au Fax: +612 9850 6200 |
| Abstract: | This review documents the uses of quantitative MS applied to colorectal cancer (CRC) proteomics for biomarker discovery and molecular pathway profiling. Investigators are adopting various labeling and label-free MS approaches to quantitate differential protein levels in cells, tumors, and plasma/serum. We comprehensively review recent uses of this technology to examine mouse models of CRC, CRC cell lines, their secretomes and subcellular fractions, CRC tumors, CRC patient plasma/serum, and stool samples. For biomarker discovery these approaches are uncovering proteins with potential diagnostic and prognostic utility, while in vitro cell culture experiments are characterizing proteomic and phosphoproteomic responses to disrupted signaling pathways due to mutations or to inhibition of drugable enzymes. |
| Keywords: | Biomarker Colorectal cancer (CRC) Mass spectrometry Quantitation |
